Skip to content

SuperTROPO (Better Diagnostics of Myocardial Infarction With a Test for Special Forms of Troponin)

SuperTROPO (Better Diagnostics of Myocardial Infarction With a Test for Special Forms of Troponin)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05858112
Acronym
SuperTROPO
Enrollment
3000
Registered
2023-05-15
Start date
2023-05-01
Completion date
2025-12-31
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction, Myocardial Ischemia

Keywords

Troponin, Myocardial ischemia, Myocardial infarction, High-sensitivity troponin T

Brief summary

The aim of this study is to investigate whether measurement of the long forms of cTnT with the novel SuperTROPO assay would improve the diagnosis of myocardial infarction in patients in the emergency department. The main goals are: 1. To assess whether measuring long forms of cTnT with the novel SuperTROPO assay and determining the ratio of long cTnT and standard high-sensitivity cTnT could separate patients with type 1 NSTEMI patients from patients with other causes of minor (\> 14ng/L) cTnT elevation in a single admission blood sample in unselected emergency department patients with clinical indication for troponin measurement. 2. To compare the level of long cTnT and the ratio of long cTnT and standard cTnT in patients with type 1 MI and various clinical patient groups admitted to emergency department with elevated standard cTnT, e.g. patients with atrial fibrillation, heart failure or renal impairment. 3. To evaluate optimal cut-off values for long cTnT and its ratio to standard cTnT in the exclusion and diagnosis of MI in a clinical setting with elevated (\>14ng/L) cTnT. 4. To evaluate how time from symptom onset and peak symptom to blood sampling, as well as comorbidities and patients' age impact the discriminative capacity of long cTnT and cTnT ratio between patients with and without type 1 MI. 5. To investigate whether information on long cTnT and its ratio to standard cTnT can be used to cut down unnecessary coronary angiographies and hospital admissions The long forms of cTnT are measured from the residual blood samples routinely collected from patients with suspected myocardial infarction.

Interventions

DIAGNOSTIC_TESTSuperTROPO novel assay to measure the long forms of cTnT

SuperTROPO novel assay to measure the long forms of cTnT

Sponsors

University of Turku
CollaboratorOTHER
Turku University Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
19 Years to 110 Years
Healthy volunteers
No

Inclusion criteria

* Patient has arrived at the emergency department and high-sensitivity cTnT test (P-TnT) has been ordered as part of the routine cardiac package of laboratory tests upon arrival * Result of \>14 ng/L of the P-TnT test included in the cardiac package * Age \> 18 * The patient or his/her legal representative has given written informed consent for participation in the study

Exclusion criteria

* unable to give informed consent * legally incompetent individuals * pregnancy * previously participated in this study

Design outcomes

Primary

MeasureTime frameDescription
Myocardial infarction type 1During the index hospitalization, that is, the hospitalization after the drawn blood samples at the emergency department. Up to 12 weeks.In brief, type 1 MI will be diagnosed when there is evidence of myocardial necrosis along with a clinical setting consistent with acute myocardial ischemia, as well as a coronary plaque rupture or erosion and superimposed thrombosis. The presence of the final diagnosis of type 1 MI by the treating clinician will be reviewed from patient records of the index hospitalization. Furthermore, patients with type 2 MI, will be identified and analyzed separately. The proportion of patients with type MI will be calculated and troponin values will be compared with patients with and without MI. .

Countries

Finland

Contacts

Primary ContactKonsta Teppo
jkitep@utu.fi00358415027333

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026